article Open AccessTop 1% cited
A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer
Clinical Cancer Research · 2006 · Vol. 12(20) · pp. 6106–6115
Michael H. Kershaw✉(Peter MacCallum Cancer Centre)Jennifer A. Westwood(Peter MacCallum Cancer Centre)Linda L. Parker(Cancer Institute (WIA))Gang Wang(Cancer Institute (WIA))Zelig Eshhar(Weizmann Institute of Science)Sharon Mavroukakis(Cancer Institute (WIA))Donald E. White(Center for Cancer Research)John R. Wunderlich(Center for Cancer Research)Silvana Canevari(Fondazione IRCCS Istituto Nazionale dei Tumori)Linda Rogers-Freezer(Center for Cancer Research)Clara C. Chen(National Institutes of Health Clinical Center)James C. Yang(Cancer Institute (WIA))Steven A. Rosenberg(Center for Cancer Research)Patrick Hwu(Center for Cancer Research)
Abstract
Large numbers of gene-modified tumor-reactive T cells can be safely given to patients, but these cells do not persist in large numbers long term. Future studies need to employ strategies to extend T cell persistence. This report is the first to document the use of genetically redirected T cells for the treatment of ovarian cancer.
CAR-T cell therapy researchVirus-based gene therapy researchImmunotherapy and Immune ResponsesMedicineOvarian cancerImmunotherapyCancerCohortPeripheral blood mononuclear cellChimeric antigen receptorImmunologyAdoptive cell transferInterleukin 2
MeSH terms
FemaleHumansOvarian NeoplasmsT-LymphocytesTransplantation, HomologousCohort StudiesPolymerase Chain ReactionImmunotherapy, AdoptiveLymphocyte TransfusionDNA PrimersPatient Selection
Funding
- National Breast Cancer Foundation
- Peter MacCallum Cancer Centre
- Medical Research Council
- National Health and Medical Research Council
Citations
1,233
FWCI
12.88
field-weighted impact
References
36
Percentile
99%
vs. same field & year
Citations per year
Cited by
Targeting folate receptor alpha for cancer treatment
Oncotarget · 2016 · 443 citations
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
Science Translational Medicine · 2011 · 2,388 citations
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
Science Translational Medicine · 2015 · 1,707 citations
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety
Leukemia · 2010 · 554 citations
Delivery technologies for cancer immunotherapy
Nature Reviews Drug Discovery · 2019 · 2,556 citations
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Nature reviews. Immunology · 2020 · 4,024 citations
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
Science Translational Medicine · 2017 · 1,724 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.